Biology:Diranersen
Diranersen (INN; developmental code names BIIB080, IONIS-MAPTRx, and ISIS-814907) is an antisense oligonucleotide (ASO) against tau which is under development for the treatment of Alzheimer's disease.[1][2][3][4] It is given by intrathecal injection.[1] The drug is under development by Ionis Pharmaceuticals and Biogen.[1][2][3] As of July 2026, it is in phase 2 clinical trials for Alzheimer's disease.[1][2][3] Diranersen has been found to decrease levels of tau in cerebrospinal fluid by 30 to 65%[3][4] and was reported to slightly slow cognitive decline, by 26%, in a preliminary phase 2 trial.[4][5] This degree of slowing is on par with that of existing anti-amyloid antibodies.[5] The drug is one of the most clinically advanced anti-tau drugs under development.[6]
See also
- Anti-tau drug
References
- ↑ 1.0 1.1 1.2 1.3 "Diranersen". 2 July 2026. https://adisinsight.springer.com/drugs/800049748.
- ↑ 2.0 2.1 2.2 "Delving into the Latest Updates on ISIS-814907 with Synapse". 20 June 2026. https://synapse.patsnap.com/drug/0cafd55ec97940528ec54909634083f2.
- ↑ 3.0 3.1 3.2 3.3 "Diranersen". 14 May 2026. https://www.alzforum.org/therapeutics/diranersen.
- ↑ 4.0 4.1 4.2 "A new sort of Alzheimer's drug shows glimmers of promise". 14 July 2026. https://www.sciencenews.org/article/new-alzheimers-drug-tau-promise.
- ↑ 5.0 5.1 "Biogen Alzheimer's drug slowed decline at rates on par with approved therapies, study shows". 14 July 2026. https://www.statnews.com/2026/07/14/biogen-alzheimers-tau-diranersen-trial-results-ionis-aaic/.
- ↑ "Biogen defends anti-tau drug after stock slides on Alzheimer's readout". 14 July 2026. https://www.fiercebiotech.com/biotech/biogen-defends-anti-tau-drug-after-stock-slides-alzheimers-readout.
 |  |
